Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results

Ravaud A., Barrios C. H., Alekseev B. Y., Tay M. H., Agarwala S. S., Yalcin S., ...More

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)

Publication Type: Conference Paper / Summary Text
Volume: 31
City: Illinois
Country: United States Of America
Hacettepe University Affiliated: Yes